Lineage reports OpRegen 36-month data: +9 ETDRS letters in extensive-coverage GA patients

Lineage Cell Therapeutics, Inc.

Mean BCVA gain of +6.2 letters (n=10) persisting through 36 months vs. +5.5 at 24 months.
Patients with extensive bleb coverage (n=5) showed mean +9.0 letters at 36 months vs. +7.4 at 24 months.
Retinal structure improvements (RPEDC, ELM) on OCT sustained in treated eyes; untreated fellow eyes declined.
Phase 2a GAlette study enrolling (NCT05626114) testing proprietary surgical delivery devices.
CEO states data challenges view that GA causes irreversible damage; effects durable after single injection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.